乳がんを患う閉経前女性を対象に、ゾラデックス™ 10.8 mgとゾラデックス 3.6 mgを比較する研究

基本情報

NCT ID

NCT01073865

ステータス

完了

試験のフェーズ

第3相

試験タイプ

介入

目標被験者数

222

治験依頼者名

AstraZeneca

概要

The purpose of this study is to examine the efficacy and safety as well as the characteristics of the female hormone and study medications after administration in pre-menopausal women with estrogen receptor positive advanced breast cancer who were randomised in a 1:1 ratio to either of the two treatment groups; the ZD9393 3.6 mg depot group or ZD9393 10.8 mg depot group, both given in combination with tamoxifen tablets.

対象疾患

介入

依頼者（Sponsor）